NICE says yes to Servier's Procoralan, but only after other treatments
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, has published draft guidance adding Servier's Procoralan (ivabradine) to the list of treatments available for patients with chronic heart failure. The draft guidance is largely in line with 2012 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure and, according to NICE, it reflects the "robust" evidence supporting existing treatments.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.